Table 2 Infection-related characteristics of cancer patients who survived or died during hospitalization of nosocomial infections caused by MDR bacteria
Characteristics | All N = 257 | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|---|
Survivor N = 229, n (%) | Non-survivor N = 28, n (%) | P-value | OR (95% CI) | P-value | ||
Sample type | ||||||
Sputum | 62 (24.1) | 53 (23.1) | 9 (32.1) | 0.293 | ||
Urine | 93 (36.2) | 91 (39.7) | 2 (7.1) | 0.001* | 0.01 (0–1.10) | 0.054 |
Blood culture | 44 (17.1) | 32 (14.0) | 12 (42.9) | < 0.001* | 1.21 (0.03–50.21) | 0.919 |
Ascites | 10 (3.9) | 9 (3.9) | 1 (3.6) | 1.000 | ||
Wounds secreta | 21 (8.2) | 20 (8.7) | 1 (3.6) | 0.565 | ||
Bronchoalveolar lavage fluid | 6 (2.3) | 4 (1.7) | 2 (7.1) | 0.262 | ||
Drainage fluid post-operation | 21 (8.2) | 20 (8.7) | 1 (3.6) | 0.565 | ||
Primary sites of infection | ||||||
Respiratory tract | 69 (26.8) | 56 (24.5) | 13 (46.4) | 0.013* | 5.36 (0.43–66.55) | 0.191 |
Urinary tract | 98 (38.1) | 94 (41.0) | 4 (14.3) | 0.006* | 0.58 (0.04–8.21) | 0.686 |
Skin and soft tissue | 19 (7.4) | 18 (7.9) | 1 (3.6) | 0.663 | ||
Thoracic cavity | 13 (5.7) | 13 (5.7) | 0 | 0.403 | ||
Abdominal cavity | 24 (9.3) | 22 (9.6) | 2 (7.1) | 0.937 | ||
Catheter related | 2 (0.8) | 2 (0.9) | 0 | 1.000 | ||
BSI | 32 (12.5) | 24 (10.5) | 8 (28.6) | 0.015* | 4.02 (0.18–89.40) | 0.379 |
Length of hospitalization | 21.0 (12.0–28.0) | 21.0 (13.0–28.0) | 11.0 (7.0–16.0) | < 0.001* | ||
≥ 21.0 | 130 (50.6) | 126 (55.0) | 4 (14.3) | < 0.001* | 0.06 (0.01–0.43) | 0.005* |
Empirical antibiotics treatment | 224 (87.2) | 198 (86.5) | 26 (92.9) | 0.512 | ||
β-lactam/β-lactamase inhibitor combinations | 41 (16.0) | 36 (15.7) | 5 (17.9) | 0.986 | ||
Cephalosporins | 22 (8.6) | 20 (8.7) | 2 (7.1) | 1.000 | ||
Carbapenems | 9 (3.5) | 9 (3.9) | 0 | 0.601 | ||
Fluoroquinolones | 22 (8.6) | 19 (8.3) | 3 (10.7) | 0.941 | ||
Aminoglycosides | 5 (1.9) | 5 (2.2) | 0 | 0.948 | ||
Combination therapy | 125 (48.6) | 109 (47.6) | 16 (57.1) | 0.340 | ||
Effective empirical antibiotics treatment | 134 (52.1) | 118 (51.5) | 16 (57.1) | 0.575 | ||
Length of antibiotics treatment (days) | 8.0 (5.0–13.0) | 8.0 (5.0–13.0) | 6.5 (4.0–9.8) | 0.143 | ||
ICU admission | 33 (12.8) | 30 (13.1) | 3 (10.7) | 0.955 | ||
Mechanical ventilation | 18 (7.0) | 14 (6.1) | 4 (14.3) | 0.227 | ||
Septic shock | 38 (14.8) | 27 (11.8) | 11 (39.3) | < 0.001* | 1.27 (0.17–9.48) | 0.814 |
Laboratory examination results | ||||||
Hemoglobin (g/L; normal range 115–150) | 106.0 (93.0–117.0) | 107.0 (94.5–118.5) | 99.0 (80.8–107.0) | 0.001* | ||
< 110 | 148 (57.6) | 125 (54.6) | 23 (82.1) | 0.005* | 9.15 (1.22–68.66) | 0.031* |
Platelet count (×109/L; normal range 125–350) | 212.0 (139.0–278.0) | 219.0 (147.5–281.5) | 123.5 (51.0–225.3) | 0.009* | ||
< 100.0 | 32 (12.5) | 21 (9.2) | 11 (39.3) | < 0.001* | 4.41 (0.61–36.91) | 0.142 |
White-cell count (×109/L; normal range 4.0–10.0) | 7.0 (4.8–10.0) | 6.9 (4.8–9.8) | 7.3 (3.4–11.6) | 0.521 | ||
> 10.0 | 64 (24.9) | 55 (24.0) | 9 (32.1) | 0.348 | ||
< 4.0 | 46 (17.9) | 39 (17.0) | 7 (25.0) | 0.299 | ||
Neutrophils count (× 109/L; normal range 1.8–6.3) | 5.3 (3.1–8.2) | 5.3 (3.1–8.0) | 6.1 (2.5–10.3) | 0.812 | ||
Lymphocytes count (×109/L; normal range 1.1–3.2) | 0.9 (0.6–1.3) | 0.9 (0.6–1.3) | 0.6 (0.3–0.9) | 0.014* | ||
< 1.0 | 152 (59.1) | 129 (56.3) | 23 (82.1) | 0.009* | 2.43 (0.29–20.48) | 0.414 |
PCT (ng/mL; normal range 0–0.5) | 0.5 (0.5–0.9) | 0.5 (0.5–0.5) | 1.2 (0.5–6.7) | 0.139 | ||
≥ 1.0 | 62 (24.1) | 46 (20.1) | 16 (57.1) | < 0.001* | 0.82 (0.14–5.00) | 0.833 |
Albumin (g/L; normal range 40–55) | 34.6 (30.0–39.0) | 35.0 (30.0–39.0) | 31.0 (26.4–34.8) | < 0.001* | ||
< 30.0 | 61 (23.7) | 49 (21.4) | 12 (42.9) | 0.012* | 3.55 (0.53–23.80) | 0.193 |